ArticleCommunications medicine2025
Contraceptive-induced menstrual changes in low- and middle-income countries: a systematic scoping review.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundContraceptive-induced menstrual changes (CIMCs) contribute substantially to women's dissatisfaction with and discontinuation of contraceptives. We summarised evidence on the prevalence, health impact, treatment, and barriers to accessing treatment for CIMC in low- and middle-income countries (LMICs).
methodsNine databases (MEDLINE, Embase, Emcare, PsycINFO, Global Health, Global Index Medicus, CINAHL, Web of Science, and Scopus) were systematically searched for studies published from January 1, 2000, to December 16, 2024. Eligible studies included reproductive-age women (15-49 years) using any modern contraceptive (excluding barrier and permanent methods) in LMICs. Findings were categorised according to the World Health Organization's Belsey definitions of frequency and severity of CIMC-related bleeding. Quantitative data were summarised using descriptive statistics and qualitative data using thematic synthesis.
resultsHere we include 321 studies conducted in 44 countries. The prevalence of CIMCs range from 0-94% and vary by contraceptive type. Two-fifths (40.2%) of the prevalence reports did not define the type of CIMC experienced by participants. The most frequently reported health impact of CIMCs is contraceptive discontinuation leading to an unmet need for contraception. Non-steroidal anti-inflammatory drugs are the most frequently investigated treatment. No studies report on the barriers to accessing treatment for CIMCs in LMICs.
conclusionCIMC impacts contraceptive users in various ways depending on the contraceptive type and user's perception of it, highlighting the importance of counselling. Primary research must use standardised definitions of CIMC to improve data quality. Investment in research and development of innovative therapeutics and novel approaches to reducing CIMC is needed to mitigate the unmet need for contraception in LMICs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.